TIDMFUM
RNS Number : 3565D
Futura Medical PLC
28 June 2021
28 June 2021
Futura Medical Announces Results Annual General Meeting
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative
products based on its proprietary, transdermal DermaSys(R) drug
delivery technology and currently focused on sexual health and
pain, today announces that at its Annual General Meeting, held
today at 10:00am BST, all resolutions were duly passed by the
shareholders.
The total number of votes received on each resolution were as
follows:
Resolution Voting for(i) % Voting against % Total votes % ISC Voted Votes
withheld(ii)
To receive and
adopt the annual
report of the
directors and
the financial
statements for
the
financial year
ended 31
December 2020
and the report
of the appointed
auditors
1 thereon. 103,106,198 94.7 5,772,128 5.3 108,878,326 37.9 32,500
------------------ -------------- ------ --------------- ---- ------------ ------------ ------------------
2 To re-elect 108,487,634 99.8 252,134 0.2 108,739,768 37.9 149,058
Angela Hildreth
as a Director of
the Company, who
retires by
rotation in
accordance
with the
Company's
articles of
association.
------------------ -------------- ------ --------------- ---- ------------ ------------ ------------------
3 To re-appoint 108,825,140 100.0 40,026 0.0 108,865,166 37.9 45,660
Grant Thornton
UK LLP as
auditor of the
Company to hold
office until the
conclusion
of the next
annual general
meeting of the
Company.
------------------ -------------- ------ --------------- ---- ------------ ------------ ------------------
4 To authorise the 108,767,186 100.0 51,332 0.0 108,818,518 37.9 92,308
Directors to
determine the
remuneration of
Grant Thornton
UK LLP as
auditor
of the Company.
------------------ -------------- ------ --------------- ---- ------------ ------------ ------------------
5 To authorise the 108,505,091 99.9 113,134 0.1 108,618,225 37.8 292,601
directors of the
Company to issue
and allot
relevant
securities (up
to 1/3
of the existing
issued share
capital)
pursuant to
section 551 of
the Companies
Act 2006.
------------------ -------------- ------ --------------- ---- ------------ ------------ ------------------
6 Disapplication of 107,966,630 99.5 520,098 0.5 108,486,728 37.8 94,098
the pre-emption
provision of
section 561 of
the Act in
connection with
an
offer of equity
securities by
way of a Rights
Issue or up to
an aggregate
nominal
value of
GBP28,707.00
(iii)
------------------ -------------- ------ --------------- ---- ------------ ------------ ------------------
7 Disapplication of 108,066,930 99.6 481,396 0.4 108,548,326 37.8 32,500
the pre-emption
provision of
section 561 of
the Act in
connection with
an
offer of equity
securities to
fund an
acquisition or a
capital
transaction
(iii)
------------------ -------------- ------ --------------- ---- ------------ ------------ ------------------
Where shareholders appointed the Chairman as their proxy with
discretion as to voting, their votes were cast in favour of the
resolution
A vote withheld is not a vote in law and is not counted towards
the votes cast "For" or "Against" a resolution.
Special Resolution (75% majority required)
The total voting rights of the Company as at 10:00 am on 24 June
2021 (the time by which shareholders wanting to vote at the AGM
were required to be entered on the register) was 287,070,971
ordinary shares of 0.2p each. The Company does not hold any shares
in treasury
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.Futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 20 3922 0900
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction (ED) through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application. MED3000 is CE marked in Europe
and the UK as a clinically proven topical treatment for adult men
with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUWUURAOUNUAR
(END) Dow Jones Newswires
June 28, 2021 08:26 ET (12:26 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
